Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PoC Phase II Double-Blind Randomised Placebo-controlled Study of VSN16R for Spasticity in Multiple Sclerosis
2014-004412-11Phase 2Unknown
- Sponsor
- Canbex Therapeutics Ltd
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) and Muscle spasm comparing VSN16R arm with Placebo arm (2 arms). Primary endpoints: Change in Mean Spasticity (NRS) from Baseline to End of Treatment and Dose-response of VSN16R on Spasticity (NRS) in Early Cohort. Status: unknown.
02
Drugs
VSN16R
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2014-004412-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004412-11.